The Capital Group Companies, Inc. 333 South Hope Street Los Angeles, CA 90071-1406

capitalgroup.com

13 October 2025

Nykode Therapeutics ASA

Oslo Bors AS (Oslo Stock Exchange) 011 47 22 41 67 90 [email protected]

Norwegian Central Depository (VPS) 011 47 22 63 52 00 [email protected]

Re: The Capital Group Companies, Inc. - Disclosure of acquisition/disposition of large shareholdings - Nykode Therapeutics ASA (the "Company")

The Capital Group Companies, Inc. ("CGC") is the parent company of Capital Research and Management Company ("CRMC") and Capital Bank & Trust Company ("CB&T"). CRMC is a U.S.-based investment management company that serves as investment manager to the American Funds family of mutual funds and institutional clients. CRMC and its investment manager affiliates manage equity assets for various investment companies through three divisions, Capital Research Global Investors, Capital International Investors and Capital World Investors. CRMC is the parent company of Capital Group International, Inc. ("CGII"), which in turn is the parent company of four investment management companies ("CGII management companies"): Capital International, Inc., Capital International Limited, Capital International Sàrl and Capital International K.K. CGII management companies and CB&T primarily serve as investment managers to institutional clients. CB&T is a U.S.-based investment management company that is a registered investment adviser and an affiliated federally chartered bank.

Neither CGC nor any of its affiliates own shares of the Company for its own account. Rather, the shares reported on this Notification are owned by accounts under the discretionary investment management of one or more of the investment management companies described above.

Pursuant to Section 4-3 of the Norwegian Securities Trading Act and the Securities Trading Act Regulations, we hereby disclose the following information.

On 10 October 2025, one or more of CGC's management companies acquired 75,057 shares of the Company, resulting in a shareholding amounting to 5.018% of total voting rights and 5.018% of total share capital. Please see the enclosed Schedule A for transaction details and Schedule B for the number of shares in the Company held by each management company in respect of which this notification relates.

For the purpose of this Report, the total voting rights figure of 326,546,444 votes and the total share capital figure of 326,546,444 shares were used to calculate the percentages. We believe these figures are correct; however, if these numbers are not accurate, please contact us as soon as possible so we may make the necessary revisions.

Should you have questions or require additional information, please contact us at (213) 486-9200 or via e-mail at [email protected].

Regards,

_____________________ Aisha Aden

Schedule A - Nykode Therapeutics ASA

The Capital Group Companies, Inc. Transactions by Management Company As of 10 October 2025

Management Company	Date of transaction	Nature of change	Price per share	Class and number of securities transacted	Votes affected
Capital Research and Management Company	10 Oct 2025	Purchase	2.1102 NOK	75,057 Common Stock	75,057

Schedule B - Nykode Therapeutics ASA

The Capital Group Companies, Inc. Holdings by Management Company As of 10 October 2025

Total Shares = Actual Shares + Lent Shares

Management Company	Number of Votes	Percent of total voting rights	Number of Shares	Percent of total shares
Capital Research and Management Company	16,387,015	5.018%	16,387,015	5.018%
The Capital Group Companies, Inc.	16,387,015	5.018%	16,387,015	5.018%

Actual Shares

Management Company	Number of Votes	Percent of total voting rights	Number of Shares	Percent of total shares
Capital Research and Management Company	16,387,015	5.018%	16,387,015	5.018%
The Capital Group Companies, Inc.	16,387,015	5.018%	16,387,015	5.018%

Lent Shares

Management Company	Number of	Percent of total	Number of	Percent of total
	Votes	voting rights	Shares	shares
The Capital Group Companies, Inc.	0	0.000%	0	0.000%

AI Terminal